月度归档： 2026 年 6 月

As food manufacturers race to get artificial dyes out of their supply chains, GRA Nutra has launched its newest colour for the US market.

Days after securing the first novel food approval for whole-food mycelium protein in the EU, The Protein Brewery has raised €18M ($20.5M) in a Series B extension round.

Demand for plant-based milk alternatives is growing steadily. There is an increasing demand for sensory quality, stability, and clean-label concepts. Consumers have indicated that they have expectations for products that offer a creamy mouthfeel, a uniform texture, and ingredient lists of a limited length. This poses a significant technological challenge for manufacturers, as plant-based raw materials frequently lack the functional properties of traditional dairy components.

Insilico Medicine will partner with SK Biopharmaceuticals to discover new artificial intelligence (AI)-based drug candidates for disorders affecting the neuroimmune area of the central nervous system (CNS), through a collaboration that could generate up to $2.5 billion for the AI-based drug developer.

June 2026, Beijing: The Green Agriculture Chain section of the fourth China International Supply Chain Expo (CISCE) brou…

2026年6月25日上午，河南科技大学农学院&″黑能量增产肥″花生高产试验研究项目启动仪式在河南科技大学隆重举行。该项目旨在通过产学研深度融合，探索和挖掘″黑能量增产肥″在花生高产背后的效果验证和机理研究，为我国油料作物单产提升提供科技支撑。 

本周速览：国内方面，甘蔗、根结线虫、蝗虫、草地贪夜蛾防控难题均有新登记/新成果落地；海外方面，多肽杀菌剂、微生物复配等新技术赛道持续升温，企业新品与合作动态也十分活跃。

Though he is trained as a gastroenterologist and scientist, Frédéric Marrache, MD, PhD, has always had something of an entrepreneurial itch. Following his post-doctoral program and a stint in management consulting, he made his way to Sanofi where he would work on early- to mid-stage drug development programs focused on immune-mediated diseases.

Researchers at Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center have genetically engineered CAR T cells that specifically target and kill bladder cancer (BCa) cells. Through their preclinical study the team, co-led by Taha Merghoub, PhD, a professor at Weill Cornell Medicine, identified the protein MUC16 as a clinically relevant target for bladder cancer, and demonstrated that direct delivery of MUC16-targeting CAR T cells into the bladder via a catheter can control bladder tumors in mice. The investigators say their study raises hopes that a similar approach may be effective in humans.